

FIGURE 1

FIG. 2

Human G Protein Coupled Receptor Family
(Receptors known as of January, 1999)

CLASS	LIGAND	NUMBER	TISSUE	PHYSIOLOGY	THERAPEUTICS
•Class I					
Rhodopsin like					
	•Amine				
	•Acetylcholine (muscarinic & nicotinic)	5	Brain, Nerves, Heart	Neurotransmitter	Acuity, Alzheimer's
	•Adrenoceptors				
	•Alpha Adrenoceptors	6	Brain, Kidney, Lung	Gluconeogenesis	Diabetes, Cardiovascular
	•Beta Adrenoceptors	3	Kidney, Heart	Muscle Contraction	Cardiovascular, Respiratory
	•Dopamine	5	Brain, Kidney, GI	Neurotransmitter	Cardiovascular, Parkinson's
	•Histamine	2	Vascular, Heart, Brain	Vascular Permeability	Anti-inflammatory, Ulcers
	•Serotonin (5-HT)	16	Most Tissues	Neurotransmitter	Depression, Insomnia, Analgesic
	•Peptide				
	•Angiotensin	2	Vascular, Liver, Kidney	Vasoconstriction	Cardiovascular, Endocrine
	•Bradykinin	1	Liver, Blood	Vasodilation,	Anti-inflammatory, Asthma
	•C5a anaphylatoxin	1	Blood	Immune System	Anti-inflammatory
	•Fmet-leu-phe	3	Blood	Chemoattractant	Anti-inflammatory
	•Interleukin-8	1	Blood	Chemoattractant	Anti-inflammatory
	•Chemokine	6	Blood	Chemoattractant	Anti-inflammatory
	•Orexin	2	Brain	Fat Metabolism	Obesity
	•Nociceptin	1	Brain	Bronchodilator, Pain	Airway Diseases, Anesthetic
	•CCK (Gastrin)	2	Gastrointestinal	Motility, Fat Absorption	Gastrointestinal, Obesity, Parkinson's
	•Endothelin	2	Heart, Bronchus, Brain	Muscle Contraction	Cardiovascular, Respiratory
	•Melanocortin	5	Kidney, Brain	Metabolic Regulation	Anti-inflammatory, Analgesics
	•Neuropeptide Y	5	Nerves, Intestine, Blood	Neurotransmitter	Behavior, Memory, Cardiovascular
	•Neurotensin	1	Brain,	CNS	Cardiovascular, Analgesic
	•Opioid	3	Brain,	CNS	Depression, Analgesic
	•Somatostatin	5	Brain, Gastrointestinal	Neurotransmitter	Oncology, Alzheimer's

APPLICATION FILING DATE: AUGUST 1, 2003
TITLE: SCREENING COMPOSITIONS FOR G PROTEIN-COUPLED RECEPTOR INTERNALIZATION, DESENSITIZATION INHIBITORY ACTIVITY
INVENTOR(S): ROBERT H. OAKLEY
APPLICATION SERIAL NO.: UNASSIGNED
ATTORNEY DOCKET NO. 033072-044

FIG. 2 (cont.)

•Tachykinin (Substance P, NKA_1)	3	Brain Nerves	Neurohormone	Depression, Analgesic
•Thrombin	3	Platelets, Blood Vessels	Coagulation	Anti-coagulant, Anti-inflammatory
•Vasopressin-like	4	Arteries, Heart, Bladder	Water Balance	Anti-diuretic, Diabetic Complications
•Galanin	1	Brain, Pancreas	Neurotransmitter	Analgesics, Alzheimer's
•Hormone protein				
•Follicle stimulating hormone	1	Ovary, Testis	Endocrine	Infertility
•Lutropin-choriogonadotropic	1	Ovary, Testis	Endocrine	Infertility
•Thyrotropin	1	Thyroid	Endocrine	Thyroidism, Metabolism
• (Rhod)opsin				
•Opsin	5	Eye	Photoreception	Ophthalmic Diseases
•Olfactory	4(~1000)	Nose	Smell	Olfactory Diseases
•Prostanoid				
•Prostaglandin	5	Arterial, Gastrointestinal	Vasodilation, Pain	Cardiovascular, Analgesic
•Lysophosphatidic Acid	2	Vessels, Heart, Lung	Inflammation	Cancer, Anti-Inflammatory
•Sphingosine-1-phosphate	2	Most Cells	Cell proliferation	Cancer
•Leukotriene	1	White Blood Cells, Bronchus	Inflammation	Asthma, Rheumatoid Arthritis
•Prostacyclin	1	Arterial, Gastrointestinal	Platelet Regulation	Cardiovascular
•Thromboxane	1	Arterial, Bronchus	Vasoconstriction	Cardiovascular, Respiratory
•Nucleotide-like				
•Adenosine	4	Vascular, Bronchus	Multiple Effects	Cardiovascular, Respiratory
•Purinoceptors	4	Vascular, Platelets	Relaxes Muscle	Cardiovascular, Respiratory
•Cannabis	2	Brain	Sensory Perception	Analgesics, Memory
•Platelet activating factor	1	Most Peripheral Tissues	Inflammation	Anti-inflammatory, Anti-asthmatic
•Gonadotropin-releasing hormone like				
•Gonadotropin-releasing hormone	1	Reproductive Organs, Pituitary	Reproduction	Prostate Cancer, Endometriosis
•Thyrotropin-releasing hormone	1	Pituitary, Brain	Thyroid Regulation	Metabolic Regulation
•Growth hormone-inhibiting factor	1	Gastrointestinal	Neuroendocrine	Oncology, Alzheimer's
•Melatonin	1	Brain, Eye, Pituitary	Neuroendocrine	Regulation of Circadian Cycle

APPLICATION FILING DATE: AUGUST 1, 2003
TITLE: METHOD OF SCREENING COMPOSITIONS FOR G PROTEIN-COUPLED RECEPTOR DESENSITIZATION INHIBITORY ACTIVITY
INVENTOR(S): ROBERT H. OAKLEY
APPLICATION SERIAL NO.: UNASSIGNED
ATTORNEY DOCKET NO. 033072-044

FIG. 2 (cont.)

•Class II				
Secretin like				
•Secretin	1	Gastrointestinal, Heart	Digestion	Obesity, Gastrointestinal
•Calcitonin	1	Bone, Brain	Calcium Resorption	Osteoporosis
•Corticotropin releasing factor/urocortin	1	Adrenal, Vascular, Brain	Neuroendocrine	Stress, Mood, Obesity
•Gastric inhibitory peptide (GIP)	1	Adrenals, Fat Cells	Sugar/Fat Metabolism	Diabetes, Obesity
•Glucagon	1	Liver, Fat Cells, Heart	Gluconeogenesis	Cardiovascular
•Glucagon-like Peptide 1 (GLP-1)	1	Pancreas, Stomach, Lung	Gluconeogenesis	Cardiovascular, Diabetes, Obesity
•Growth hormone-releasing hormone	1	Brain	Neuroendocrine	Growth Regulation
•Parathyroid hormone	1	Bone, Kidney	Calcium Regulation	Osteoporosis
•PACAP	1	Brain, Pancreas, Adrenals	Metabolism	Metabolic Regulation
•Vasoactive intestinal polypeptide (VIP)	1	Gastrointestinal	Motility	Gastrointestinal
•Class III				
•Metabotropic Glutamate	7	Brain	Sensory Perception	Hearing, Vision
•$GABA_B$	1	Brain	Neurotransmitter	Mood Disorders
•Extracellular Calcium Sensing	1	Parathyroid, Kidney, GI Tract	Calcium Regulation	Cataracts, GI Tumors

APPLICATION FILING DATE: AUGUST 1, 2003
TITLE: METHOD OF SCREENING COMPOSITIONS FOR G PROTEIN-COUPLED RECEPTOR DESENSITIZATION INHIBITORY ACTIVITY
INVENTOR(S): ROBERT H. OAKLEY
APPLICATION SERIAL NO.: UNASSIGNED
ATTORNEY DOCKET NO. 033072-044

Figure 3

G protein-coupled receptors:
(Division into Class A
Or Class B)

1. **A1 adenosine receptor** [Homo sapiens]. ACCESSION AAB25533
NPIVYAF RIQKFRVTFL KIWNDHFRCQ PAPPIDEDLP EERPDD
Class A

2. **adrenergic, alpha -1B-, receptor** [Homo sapiens]. ACCESSION NP_000670
npiiypc sskefkrafv rilgcqcrgr grrrrrrrrr lggcaytyrp wtrggslers qsrkdsldds gsclsgsqrt lpsaspspgy lgrgapppve lcafpewkap gallslpape ppgrrgrhds gplftfkllt epespgtdgg asnggceaaa dvangqpgfk snmplapgqf
Class A

3. **adrenergic receptor alpha-2A** [Homo sapiens]. ACCESSION AAG00447
npviytifn hdfrrafkki lcrgdrkriv
Class A

4. **alpha-2B-adrenergic receptor** - human. ACCESSION A37223
npviytifn qdfrrafrri lcrpwtqtaw
Class A

5. **alpha-2C-adrenergic receptor** - human. ACCESSION A31237
npviytvfn qdfrpsfkhi lfrrrrrgfr q
Class A

6. **beta-1-adrenergic receptor** [Homo sapiens]. ACCESSION NP_000675
npiiycrs pdfrkafqgl lccarraarr rhathgdrpr asgclarpgp ppspgaasdd ddddvvgatp parllepwag cnggaaadsd ssldepcrpg faseskv
Class A

7. **beta-2 adrenergic receptor.** ACCESSION P07550
npliycrsp dfriafqell clrrsslkay gngyssngnt 361 geqsgyhveq ekenkllced lpgtedfvgh qgtvpsdnid sqgrncstnd sll
Class A

8. **dopamine receptor D1** [Homo sapiens]. ACCESSION NP_000785
npii yafnadfrka fstllgcyrl cpatnnaiet vsinnngaam fsshheprgs iskecnlvyl iphavgssed lkkeeaagia rpleklspal svildydtdv slekiqpitq ngqhpt
Class A

9. **D(2) dopamine receptor.** ACCESSION P14416
npiiyttfn iefrkaflki lhc
Class A

Figure 3 (cont.)

10. **d3 dopamine receptor** - human. ACCESSION G01977
np viyttfnief rkaflkilsc
Class A

11. **dopamine receptor D4** - human. ACCESSION DYHUD4
npviytv fnaefrnvfr kalracc
Class A

12. **dopamine receptor D5** - human. ACCESSION DYHUD5
npviya fnadfqkvfa qllgcshfcs rtpvetvnis nelisynqdi vfhkeiaaay ihmmpnavtp gnrevdndee egpfdrmfqi yqtspdgdpv aesvweldce geisldkitp ftpngfh
Class A

13. **muscarinic acetylcholine receptor M1** [Homo sapiens]. ACCESSION NP_000729
npmcyal cnkafrdtfr llllcrwdkr rwrkipkrpg svhrtpsrqc
Class A

14. **muscarinic acetylcholine receptor M2** [Homo sapiens]. ACCESSION NP_000730
npacy alcnatfkkt fkhllmchyk nigatr
Class A

15. **muscarinic acetylcholine receptor M3 [Homo sapiens].** ACCESSION NP_000731
n pvcyalcnkt frttfkmlll cqcdkkkrrk qqyqqrqsvi fhkrapeqal
Class A

16. **muscarinic acetylcholine receptor M4** [Homo sapiens]. ACCESSION NP_000732
npa cyalcnatfk ktfrhlllcq yrnigtar
Class A

17. **m5 muscarinic receptor.** locus HUMACHRM ACCESSION AAA51569
npicyalcnr tfrktfkmll lcrwkkkkve eklywqgnsk lp
Class A

18. **5-hydroxytryptamine (serotonin) receptor 1A** [Homo sapiens]. ACCESSION BAA90449
npviy ayfnkdfqna fkkiikckf
Class A

19. **5-hydroxytryptamine (serotonin) receptor 1B** [Homo sapiens]. ACCESSION BAA94455
npiiyt msnedfkqaf hklirfkcts
Class A

20. **5-hydroxytryptamine (serotonin) receptor 1E** [Homo sapiens]. ACCESSION BAA94458
n pllytsfned fklafkklir cre
Class A

Figure 3 (cont.)

21. **OLFACTORY RECEPTOR 6A1**. ACCESSION O95222
npiiyclrnq evkralccil hlyqhqdpdp kkgsrnv
Class A

22. **OLFACTORY RECEPTOR 2C1**. ACCESSION O95371
npliy tlrnmevkga lrrllgkgre vg
Class A

23. **angiotensin receptor 1 [Homo sapiens].** ACCESSION NP_033611
npl fygflgkkfk ryflqllkyi ppkakshsnl ***stk***msflsyr psdnv***sss***tk kpapcfeve
Class B

24. **angiotensin receptor 2** [Homo sapiens]. ACCESSION NP_000677
npflycf vgnrfqqklr svfrvpitwl qgkresmscr **kssslremet** fvs
Class B

25. **interleukin 8 receptor beta (CXCR2)** [Homo sapiens]. ACCESSION NM_001557
NPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVGSSSGHTSTTL
Class B

26. **cx3c chemokine receptor 1** (cx3cr1) (fractalkine receptor)
ACCESSION P49238
np liyafagekf rrylyhlygk clavlcgrsv hvdf**sssesq** rsrhgsvl**ss** nftyhtsdgd allll
Class B

27. **neurotensin receptor - human.** ACCESSION S29506
n pilynlvsan frhiflatla clcpvwrrrr krpafsrkad **svss**nhfl**ss** natretly
Class B

28. **SUBSTANCE-P RECEPTOR (SPR)** (NK-1 RECEPTOR) (NK-1R). ACCESSION P25103
npiiycclnd rfrlgfkhaf rccpfisagd yeglemkstr ylqtqgsvyk vsrlet***ti***s***t***vvgaheeepe dgpkat**pssl**
dltsncs**ssrs** dsktmtesfs fssnvls
Class B

29. **vasopressin receptor type 2** [Homo sapiens]. ACCESSION AAD16444
npwiyasfss svsselrsll ccargrtpps lgpqdes***ctt*** **assslakd*ts s***
Class B

30. **thyrotropin-releasing hormone receptor** - human. ACCESSION JN0708
npviy nlmsqkfraa frklcnckqk ptekpanysv alnysvikes dhf***st***elddi ***tvtdtylsat*** kvsfddtcla sevsfsqs
Class B

Figure 3 (cont.)

31. **oxytocin receptor - human.** ACCESSION A55493
npwiym lftghlfhel vqrflccsas ylkgrrlget saskksnsss fvlshrsssq rscsqpsta
Class B

32. **neuromedin U receptor [Homo sapiens].** ACCESSION AAG24793
npvlyslmssrfretfqealclgacchrlrprhsshslsrmttgstlcdvgslgswvhplagndgpeaqqetdps
Class B

33. **gastrin receptor.** ACCESSION AAC37528
nplvy cfmhrrfrqa cletcarccp rpprarpral pdedpptpsi aslsrlsytt isflgpg
Class B

34. **galanin receptor 3 [Homo sapiens].** ACCESSION 10879541
nplv yalasrhfra rfrrlwpcgr rrrhrarral rrvrpassgp pgcpgdarps grllagggqg pepregpvhg geaargpe
Class A

35. **edg-1** - human. ACCESSION A35300
npiiy tltnkemrra firimscckc psgdsagkfk rpiiagmefs rsksdnsshp 361 qkdegdnpet imssgnvnss s
Class A

36. **central cannabinoid receptor** [Homo sapiens]. ACCESSION NP_057167
npiiyalr skdlrhafrs mfpscegtaq pldnsmgdsd clhkhannaa svhraaesci kstvkiakvt msvstdtsae al
Class A

37. **delta opioid receptor** - human. ACCESSION I38532
npvlyaf ldenfkrcfr qlcrkpcgrp dpssfsrpre atarervtac tpsdgpgggr aa
Class A

38. proteinase activated receptor 2 (PAR-2) human. ACCESSION P55085
dpfvyyfvshdfrdhaknallcrsvrtvkqmqvsltskkhsrkssssyssssttvktsy
Class A

39. **vasopressive intestinal peptide receptor (VIPR) rat.** ACCESSION NM_012685
NGEVQAELRRKWRRWHLQGVLGWSSKSQHPWGGSNGATCSTQVSMLTRVSPSARR SSSFQAEVSLV
Class B

FIGURE 4

The mutated amino acid at the second position of the DRY motif is underlined.

VASOPRESSIN V2 RECEPTOR - (Human)
accession P30518

R137H

```
  1 MLMASTTSAV PGHPSLPSLP SNSSQERPLD TRDPLLARAE LALLSIVFVA VALSNGLVLA
 61 ALARRGRRGH WAPIHVFIGH LCLADLAVAL FQVLPQLAWK ATDRFRGPDA LCRAVKYLQM
121 VGMYASSYMI LAMTLDHHRA ICRPMLAYRH GSGAHWNRPV LVAWAFSLLL SLPQLFIFAQ
181 RNVEGGSGVT DCWACFAEPW GRRTYVTWIA LMVFVAPTLG IAACQVLIFR EIHASLVPGP
241 SERPGGRRRG RRTGSPGEGA HVSAAVAKTV RMTLVIVVVY VLCWAPFFLV QLWAAWDPEA
301 PLEGAPFVLL MLLASLNSCT NPWIYASFSS SVSSELRSLL CCARGRTPPS LGPQDESCTT
361 ASSSLAKDTS S
```

(SEQ ID NO:40)

ALPHA-1B ADRENERGIC RECEPTOR (ALPHA 1B-ADRENOCEPTOR).
(Golden hamster)
ACCESSION P18841
R143E

```
  1 MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAISVGL VLGAFILFAI
 61 VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
121 WAAVDVLCCT ASILSLCAIS IDEYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
181 LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
241 VMKEMSNSKE LTLRIHSKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
301 GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
361 RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
421 SASPSPGYLG RGAQPPLELC AYPEWKSGAL LSLPEPPGRR GRLDSGPLFT FKLLGEPESP
481 GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF
```

(SEQ ID NO:41)

R143A

```
  1 MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAISVGL VLGAFILFAI
 61 VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
121 WAAVDVLCCT ASILSLCAIS IDAYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
181 LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
241 VMKEMSNSKE LTLRIHSKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
301 GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
361 RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
421 SASPSPGYLG RGAQPPLELC AYPEWKSGAL LSLPEPPGRR GRLDSGPLFT FKLLGEPESP
481 GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF
```

(SEQ ID NO:42)

FIG. 4 (cont.)

R143H

```
  1 MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAISVGL VLGAFILFAI
 61 VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
121 WAAVDVLCCT ASILSLCAIS IDHYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
181 LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
241 VMKEMSNSKE LTLRIHSKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
301 GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
361 RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
421 SASPSPGYLG RGAQPPLELC AYPEWKSGAL LSLPEPPGRR GRLDSGPLFT FKLLGEPESP
481 GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF
```

(SEQ ID NO:43)

R143N

```
  1 MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAISVGL VLGAFILFAI
 61 VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
121 WAAVDVLCCT ASILSLCAIS IDNYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
181 LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
241 VMKEMSNSKE LTLRIHSKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
301 GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
361 RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
421 SASPSPGYLG RGAQPPLELC AYPEWKSGAL LSLPEPPGRR GRLDSGPLFT FKLLGEPESP
481 GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF
```

(SEQ ID NO:44)

Angiotensin II Receptor, Type 1 (AT1A) [Rattus norvegicus].
ACCESSION NP_112247

R126H

```
  1 MALNSSAEDG IKRIQDDCPK AGRHSYIFVM IPTLYSIIFV VGIFGNSLVV IVIYFYMKLK
 61 TVASVFLLNL ALADLCFLLT CPLWAVYTAM EYRWPFGNHL CKIASASVTF NLYASVFLLT
121 CLSIDHYLAI VHPMKSRLRR TMLVAKVTCI IIWLMAGLAS LPAVIHRNVY FIENTNITVC
181 AFHYESRNST LPIGLGLTKN ILGFLFPFLI ILTSYTLIWK ALKKAYEIQK NKPRNDDIFR
241 IIMAIVLFFF FSWVPHQIFT FLDVLIQLGV IHDCKISDIV DTAMPITICI AYFNNCLNPL
301 FYGFLGKKFK KYFLQLLKYI PPKAKSHSSL STKMSTLSYR PSDNMSSSAK KPASCFEVE
```

(SEQ ID NO:45)

Figure 5

A. Amino Acid sequence of the hGPR3- Enhanced Receptor

MMWGAGSPLAWLSAGSGNVNVSSVGPAEGPTGPAAPLPSPKAWDVVLCISGTLVSCENA
LVVAIIVGTPAFRAPMFLLVGSLAVADLLAGLGLVLHFAAVFCIGSAEMSLVLVGVLAM
AFTASIGSLLAITVDRYLSLYNALTYYSETTVTRTYVMLALVWGGALGLGLLPVLAWNC
LDGLTTCGVVYPLSKNHLVVLAIAFFMVFGIMLQLYAQICRIVCRHAQQIALQRHLLPA
SHYVATRKGIATLAVVLGAFAACWLPFTVYCLLGDAHSPPLYTYLTLLPATYNSMINPI
IYAFRNQDVQKVLWAVCCCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 46)

B. Nucleotide sequence of the hGPR3- Enhanced Receptor

ATGATGTGGGGTGCAGGCAGCCCTCTGGCCTGGCTCTCAGCTGGCTCAGGCAACGTGAA
TGTAAGCAGCGTGGGCCCAGCAGAGGGGCCCACAGGTCCAGCCGCACCACTGCCCTCGC
CTAAGGCCTGGGATGTGGTGCTCTGCATCTCAGGCACCCTGGTGTCCTGCGAGAATGCG
CTAGTGGTGGCCATCATCGTGGGCACTCCTGCCTTCCGTGCCCCCATGTTCCTGCTGGT
GGGCAGCCTGGCCGTGGCAGACCTGCTGGCAGGCCTGGGCCTGGTCCTGCACTTTGCTG
CTGTCTTCTGCATCGGCTCAGCGGAGATGAGCCTGGTGCTGGTTGGCGTGCTGGCAATG
GCCTTTACYGCCAGCATCGGCAGTCTACTGGCCATCACTGTCGACCGCTACCTTTCTCT
GTACAATGCCCTCACCTACTATTCAGAGACAACAGTGACACGGACCTATGTGATGCTGG
CCTTAGTGTGGGGAGGTGCCCTGGGCCTGGGGCTGCTGCCTGTGCTGGCCTGGAACTGC
CTGGATGGCCTGACCACATGTGGCGTGGTTTATCCACTCTCCAAGAACCATCTGGTAGT
TCTGGCCATTGCCTTCTTCATGGTGTTTGGCATCATGCTGCAGCTCTACGCCCAAATCT
GCCGCATCGTCTGCCGCCATGCCCAGCAGATTGCCCTTCAGCGGCACCTGCTGCCTGCC
TCCCACTATGTGGCCACCCGCAAGGGCATTGCCACACTGGCCGTGGTGCTTGGAGCCTT
TGCCGCCTGCTGGTTGCCCTTCACTGTCTACTGCCTGCTGGGTGATGCCCACTCTCCAC
CTCTCTACACCTATCTTACCTTGCTCCCTGCCACCTACAACTCCATGATCAACCCTATC
ATCTACGCCTTCCGCAACCAGGATGTGCAGAAAGTGCTGTGGGCTGTCTGCTGCTGCTG
TGCGGCCGCACGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCA
CCGCCAGcTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 47)

Figure 5 (continued)

C. Amino Acid sequence of the hGPR6- Enhanced Receptor

MNASAASLNDSQVVVVAAEGAAAAATAAGGPDTGEWGPPAAAALGAGGGANGSLELSSQ
LSAGPPGLLLPAVNPWDVLLCVSGTVIAGENALVVALIASTPALRTPMFVLVGSLATAD
LLAGCGLILHFVFQYLVPSETVSLLTVGFLVASFAASVSSLLAITVDRYLSLYNALTYY
SRRTLLGVHLLLAATWTVSLGLGLLPVLGWNCLAERAACSVVRPLARSHVALLSAAFFM
VFGIMLHLYVRICQVVWRHAHQIALQQHCLAPPHLAATRKGVGTLAVVLGTFGASWLPF
AIYCVVGSHEDPAVYTYATLLPATYNSMINPIIYAFRNQEIQRALWLLLCGCAAARGRT
PPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 48)

D. Nucleotide sequence of the hGPR6- Enhanced Receptor

ATGAACGCGAGCGCCGCCTCGCTCAACGACTCCCAGGTGGTGGTAGTGGCGGCCGAAGG
AGCGGCGGCGGCGGCCACAGCAGCAGGGGGGCCGGACACGGGCGAATGGGGACCCCCTG
CTGCGGCGGCTCTAGGAGCCGGCGGCGGAGCTAATGGGTCTCTGGAGCTGTCCTCGCAG
CTGTCGGCTGGGCCACCGGGACTCCTGCTGCCAGCGGTGAATCCGTGGGACGTGCTCCT
GTGCGTGTCGGGGACAGTGATCGCTGGAGAAAACGCGCTGGTGGTGGCGCTCATCGCGT
CCACTCCGGCGCTGCGCACGCCCATGTTCGTGCTGGTAGGCAGCCTGGCCACCGCTGAC
CTGTTGGCGGGCTGTGGCCTCATCTTGCACTTTGTGTTCCAGTACTTGGTGCCCTCGGA
GACTGTGAGTCTGCTCACGGTGGGCTTCCTCGTGGCCTCCTTCGCCGCCTCTGTCAGCA
GCCTGCTGGCCATTACGGTGGACCGCTACCTGTCCCTGTATAACGCGCTCACCTATTAC
TCGCGCCGGACCCTGTTGGGCGTGCACCTCCTGCTTGCCGCCACTTGGACCGTGTCCCT
AGGCCTGGGGCTGCTGCCCGTGCTGGGCTGGAACTGCCTGGCAGAGCGCGCCGCCTGCA
GCGTGGTGCGCCCGCTGGCGCGCAGCCACGTGGCTCTGCTCTCCGCCGCCTTCTTCATG
GTCTTCGGCATCATGCTGCACCTGTACGTGCGCATCTGCCAGGTGGTCTGGCGCCACGC
GCACCAGATCGCGCTGCAGCAGCACTGCCTGGCGCCACCCCATCTCGCTGCCACCAGAA
AGGGTGTGGGTACACTGGCTGTGGTGCTGGGCACTTTCGGCGCCAGCTGGCTGCCCTTC
GCCATCTATTGCGTGGTGGGCAGCCATGAGGACCCGGCGGTCTACACTTACGCCACCCT
GCTGCCCGCCACCTACAACTCCATGATCAATCCCATCATCTATGCCTTCCGCAACCAGG
AGATCCAGCGCGCCCTGTGGCTCCTGCTCTGTGGCTGTGCGGCCGCACGGGGACGCACC
CCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAA
GGACACTTCATCGTGA
(SEQ ID No: 49)

Figure 5 (continued)

E. Amino Acid sequence of the hGPR12- Enhanced Receptor

MNEDLKVNLSGLPRDYLDAAAAENISAAVSSRVPAVEPEPELVVNPWDIVLCTSGTLIS
CENAIVVLIIFHNPSLRAPMFLLIGSLALADLLAGIGLITNFVFAYLLQSEATKLVTIG
LIVASFSASVCSLLAITVDRYLSLYYALTYHSERTVTFTYVMLVMLWGTSICLGLLPVM
GWNCLRDESTCSVVRPLTKNNAAILSVSFLFMFALMLQLYIQICKIVMRHAHQIALQHH
FLATSHYVTTRKGVSTLAIILGTFAACWMPFTLYSLIADYTYPSIYTYATLLPATYNSI
INPVIYAFRNQEIQKALCLICCGCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 50)

F. Nucleotide sequence of the hGPR12- Enhanced Receptor

ATGAATGAAGACCTGAAGGTCAATTTAAGCGGGCTGCCTCGGGATTATTTAGATGCCGC
TGCTGCGGAGAACATCTCGGCTGCTGTCTCCTCCCGGGTTCCTGCCGTAGAGCCAGAGC
CTGAGCTCGTAGTCAACCCCTGGGACATTGTCTTGTGTACCTCGGGAACCCTCATCTCC
TGTGAAAATGCCATTGTGGTCCTTATCATCTTCCACAACCCCAGCCTGCGAGCACCCAT
GTTCCTGCTAATAGGCAGCCTGGCTCTTGCAGACCTGCTGGCCGGCATTGGACTCATCA
CCAATTTTGTTTTTGCCTACCTGCTTCAGTCAGAAGCCACCAAGCTGGTCACGATCGGC
CTCATTGTCGCCTCTTTCTCTGCCTCTGTCTGCAGCTTGCTGGCTATCACTGTTGACCG
CTACCTCTCACTGTACTACGCTCTGACGTACCATTCGGAGAGGACGGTCACGTTTACCT
ATGTCATGCTCGTCATGCTCTGGGGGACCTCCATCTGCCTGGGGCTGCTGCCCGTCATG
GGCTGGAACTGCCTCCGAGACGAGTCCACCTGCAGCGTGGTCAGACCGCTCACCAAGAA
CAACGCGGCCATCCTCTCGGTGTCCTTCCTCTTCATGTTTGCGCTCATGCTTCAGCTCT
ACATCCAGATCTGTAAGATTGTGATGAGGCACGCCCATCAGATAGCCCTGCAGCACCAC
TTCCTGGCCACGTCGCACTATGTGACCACCCGGAAAGGGGTCTCCACCCTGGCTATCAT
CCTGGGGACGTTTGCTGCTTGCTGGATGCCTTTCACCCTCTATTCCTTGATAGCGGATT
ACACCTACCCCTCCATCTATACCTACGCCACCCTCCTGCCCGCCACCTACAATTCCATC
ATCAACCCTGTCATATATGCTTTCAGAAACCAAGAGATCCAGAAAGCGCTCTGTCTCAT
TTGCTGCGGCTGCGCGGCCGCACGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATG
AGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 51)

Figure 5 (continued)

G. Amino Acid sequence of the hSREB3- Enhanced Receptor

MANTTGEPEEVSGALSPPSASAYVKLVLLGLIMCVSLAGNAILSLLVLKERALHKAPYY
FLLDLCLADGIRSAVCFPFVLASVRHGSSWTFSALSCKIVAFMAVLFCFHAAFMLFCIS
VTRYMAIAHHRFYAKRMTLWTCAAVICMAWTLSVAMAFPPVFDVGTYKFIREEDQCIFE
HRYFKANDTLGFMLMLAVLMAATHAVYGKLLLFEYRHRKMKPVQMVPAISQNWTFHGPG
ATGQAAANWIAGFGRGPMPPTLLGIRQNGHAASRRLLGMDEVKGEKQLGRMFYAITLLF
LLLWSPYIVACYWRVFVKACAVPHRYLATAVWMSFAQAAVNPIVCFLLNKDLKKCLRTH
APCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 52)

H. Nucleotide sequence of the hSREB3- Enhanced Receptor

ATGGCCAACACTACCGGAGAGCCTGAGGAGGTGAGCGGCGCTCTGTCCCCACCGTCCGC
ATCAGCTTATGTGAAGCTGGTACTGCTGGGACTGATTATGTGCGTGAGCCTGGCGGGTA
ACGCCATCTTGTCCCTGCTGGTGCTCAAGGAGCGTGCCCTGCACAAGGCTCCTTACTAC
TTCCTGCTGGACCTGTGCCTGGCCGATGGCATACGCTCTGCCGTCTGCTTCCCCTTTGT
GCTGGCTTCTGTGCGCCACGGCTCTTCATGGACCTTCAGTGCACTCAGCTGCAAGATTG
TGGCCTTTATGGCCGTGCTCTTTTGCTTCCATGCGGCCTTCATGCTGTTCTGCATCAGC
GTCACCCGCTACATGGCCATCGCCCACCACCGCTTCTACGCCAAGCGCATGACACTCTG
GACATGCGCGGCTGTCATCTGCATGGCCTGGACCCTGTCTGTGGCCATGGCCTTCCCAC
CTGTCTTTGACGTGGGCACCTACAAGTTTATTCGGGAGGAGGACCAGTGCATCTTTGAG
CATCGCTACTTCAAGGCCAATGACACGCTGGGCTTCATGCTTATGTTGGCTGTGCTCAT
GGCAGCTACCCATGCTGTCTACGGCAAGCTGCTCCTCTTCGAGTATCGTCACCGCAAGA
TGAAGCCAGTGCAGATGGTGCCAGCCATCAGCCAGAACTGGACATTCCATGGTCCCGGG
GCCACCGGCCAGGCTGCTGCCAACTGGATCGCCGGCTTTGGCCGTGGGCCCATGCCACC
AACCCTGCTGGGTATCCGGCAGAATGGGCATGCAGCCAGCCGGCGGCTACTGGGCATGG
ACGAGGTCAAGGGTGAAAAGCAGCTGGGCCGCATGTTCTACGCGATCACACTGCTCTTT
CTGCTCCTCTGGTCACCCTACATCGTGGCCTGCTACTGGCGAGTGTTTGTGAAAGCCTG
TGCTGTGCCCCACCGCTACCTGGCCACTGCTGTTTGGATGAGCTTCGCCCAGGCTGCCG
TCAACCCAATTGTCTGCTTCCTGCTCAACAAGGACCTCAAGAAGTGCCTGAGGACTCAC
GCCCCCTGCGCGGCCGCACGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTC
CTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 53)

Figure 5 (continued)

I. Amino Acid sequence of the hSREB2- Enhanced Receptor

MANYSHAADNILQNLSPLTAFLKLTSLGFIIGVSVVGNLLISILLVKDKTLHRAPYYFL
LDLCCSDILRSAICFPFVFNSVKNGSTWTYGTLTCKVIAFLGVLSCFHTAFMLFCISVT
RYLAIAHHRFYTKRLTFWTCLAVICMVWTLSVAMAFPPVLDVGTYSFIREEDQCTFQHR
SFRANDSLGFMLLLALILLATQLVYLKLIFFVHDRRKMKPVQFVAAVSQNWTFHGPGAS
GQAAANWLAGFGRGPTPPTLLGIRQNANTTGRRRLLVLDEFKMEKRISRMFYIMTFLFL
TLWGPYLVACYWRVFARGPVVPGGFLTAAVWMSFAQAGINPFVCIFSNRELRRCFSTTL
LYCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 54)

J. Nucleotide sequence of the hSREB2- Enhanced Receptor

ATGGCGAACTATAGCCATGCAGCTGACAACATTTTGCAAAATCTCTCGCCTCTAACAGC
CTTTCTGAAACTGACTTCCTTGGGTTTCATAATAGGAGTCAGCGTGGTGGGCAACCTCC
TGATCTCCATTTTGCTAGTGAAAGATAAGACCTTGCATAGAGCACCTTACTACTTCCTG
TTGGATCTTTGCTGTTCAGATATCCTCAGATCTGCAATTTGTTTCCCATTTGTGTTCAA
CTCTGTCAAAAATGGCTCTACCTGGACTTATGGGACTCTGACTTGCAAAGTGATTGCCT
TTCTGGGGGTTTTGTCCTGTTTCCACACTGCTTTCATGCTCTTCTGCATCAGTGTCACC
AGATACTTAGCTATCGCCCATCACCGCTTCTATACAAAGAGGCTGACCTTTTGGACGTG
TCTGGCTGTGATCTGTATGGTGTGGACTCTGTCTGTGGCCATGGCATTTCCCCCGGTTT
TAGACGTGGGCACTTACTCATTCATTAGGGAGGAAGATCAATGCACCTTCCAACACCGC
TCCTTCAGGGCTAATGATTCCTTAGGATTTATGCTGCTTCTtGCTCTCATCCTCCTAGC
CACACAGCTTGTCTACCTCAAGCTGATATTTTTCGTCCACGATCGAAGAAAAATGAAGC
CAGTCCAGTTTGTAGCAGCAGTCAGCCAGAACTGGACTTTTCATGGTCCTGGAGCCAGT
GGCCAGGCAGCTGCCAATTGGCTAGCAGGATTTGGAAGGGGTCCCACACCACCCACCTT
GCTGGGCATCAGGCAAAATGCAAACACCACAGGCAGAAGAAGGCTATTGGTCTTAGACG
AGTTCAAAATGGAGAAAAGAATCAGCAGAATGTTCTATATAATGACTTTTCTGTTTCTA
ACCTTGTGGGGCCCCTACCTGGTGGCCTGTTATTGGAGAGTTTTTGCAAGAGGGCCTGT
AGTACCAGGGGGATTTCTAACAGCTGCTGTCTGGATGAGTTTTGCCCAAGCAGGAATCA
ATCCTTTTGTCTGCATTTTCTCAAACAGGGAGCTGAGGCGCTGTTTCAGCACAACCCTT
CTTTACTGCGCGGCCGCACGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTC
CTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 55)

Figure 5 (continued)

K. Amino Acid sequence of the hGPR8- Enhanced Receptor

MQAAGHPEPLDSRGSFSLPTMGANVSQDNGTGHNATFSEPLPFLYVLLPAVYSGICAVG
LTGNTAVILVILRAPKMKTVTNVFILNLAVADGLFTLVLPVNIAEHLLQYWPFGELLCK
LVLAVDHYNIFSSIYFLAVMSVDRYLVVLATVRSRHMPWRTYRGAKVASLCVWLGVTVL
VLPFFSFAGVYSNELQVPSCGLSFPWPERVWFKASRVYTLVLGFVLPVCTICVLYTDLL
RRLRAVRLRSGAKALGKARRKVTVLVLVVLAVCLLCWTPFHLASVVALTTDLPQTPLVI
SMSYVITSLSYANSCLNPFLYAFLDDNFRKNFRSILRCAAARGRTPPSLGPQDESCTTA
SSSLAKDTSS
(SEQ ID No: 56)

L. Nucleotide sequence of the hGPR8- Enhanced Receptor

ATGCAGGCCGCTGGGCACCCAGAGCCCCTTGACAGCAGGGGCTCCTTCTCCCTCCCCAC
GATGGGTGCCAACGTCTCTCAGGACAATGGCACTGGCCACAATGCCACCTTCTCCGAGC
CACTGCCGTTCCTCTATGTGCTCCTGCCCGCCGTGTACTCCGGGATCTGTGCTGTGGGG
CTGACTGGCAACACGGCCGTCATCCTTGTAATCCTAAGGGCGCCCAAGATGAAGACGGT
GACCAACGTGTTCATCCTGAACCTGGCCGTCGCCGACGGGCTCTTCACGCTGGTACTGC
CCGTCAACATCGCGGAGCACCTGCTGCAGTACTGGCCCTTCGGGGAGCTGCTCTGCAAG
CTGGTGCTGGCCGTCGACCACTACAACATCTTCTCCAGCATCTACTTCCTAGCCGTGAT
GAGCGTGGACCGATACCTGGTGGTGCTGGCCACCGTGAGGTCCCGCCACATGCCCTGGC
GCACCTACCGGGGGGCGAAGGTCGCCAGCCTGTGTGTCTGGCTGGGCGTCACGGTCCTG
GTTCTGCCCTTCTTCTCTTTCGCTGGCGTCTACAGCAACGAGCTGCAGGTCCCAAGCTG
TGGGCTGAGCTTCCCGTGGCCCGAGCGGGTCTGGTTCAAGGCCAGCCGTGTCTACACTT
TGGTCCTGGGCTTCGTGCTGCCCGTGTGCACCATCTGTGTGCTCTACACAGACCTCCTG
CGCAGGCTGCGGGCCGTGCGGCTCCGCTCTGGAGCCAAGGCTCTAGGCAAGGCCAGGCG
GAAGGTGACCGTCCTGGTCCTCGTCGTGCTGGCCGTGTGCCTCCTCTGCTGGACGCCCT
TCCACCTGGCCTCTGTCGTGGCCCTGACCACGGACCTGCCCCAGACCCCACTGGTCATC
AGTATGTCCTACGTCATCACCAGCCTCAGCTACGCCAACTCGTGCCTGAACCCCTTCCT
CTACGCCTTTCTAGATGACAACTTCCGGAAGAACTTCCGCAGCATATTGCGGTGCGCGG
CCGCACGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACCGCC
AGCTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 57)

Figure 5 (continued)

M. Amino Acid sequence of the hGPR22-Enhanced Receptor

MCFSPILEINMQSESNITVRDDIDDINTNMYQPLSYPLSFQVSLTGFLMLEIVLGLGSN
LTVLVLYCMKSNLINSVSNIITMNLHVLDVIICVGCIPLTIVILLLSLESNTALICCFH
EACVSFASVSTAINVFAITLDRYDISVKPANRILTMGRAVMLMISIWIFSFFSFLIPFI
EVNFFSLQSGNTWENKTLLCVSTNEYYTELGMYYHLLVQIPIFFFTVVVMLITYTKILQ
ALNIRIGTRFSTGQKKKARKKKTISLTTQHEATDMSQSSGGRNVVFGVRTSVSVIIALR
RAVKRHRERRERQKRVFRMSLLIISTFLLCWTPISVLNTTILCLGPSDLLVKLRLCFLV
MAYGTTIFHPLLYAFTRQKFQKVLKSKMKKRVVCAAARGRTPPSLGPQDESCTTASSSL
AKDTSS
(SEQ ID No: 58)

N. Nucleotide sequence of the hGPR22-Enhanced Receptor

ATGTGTTTTTCTCCcaTTCTGGAAATCAACATGCAGTCTGAATCTAACATTACAGTGCG
AGATGACATTGATGACATCAACACCAATATGTACCAACCACTATCATATCCGTTAAGCT
TTCAAGTGTCTCTCACCGGATTTCTTATGTTAGAAATTGTGTTGGGACTTGGCAGCAAC
CTCACTGTATTGGTACTTTACTGCATGAAATCCAACTTAATCAACTCTGTCAGTAACAT
TATTACAATGAATCTTCATGTACTTGATGTAATAATTTGTGTGGGATGTATTCCTCTAA
CTATAGTTATCCTTCTGCTTTCACTGGAGAGTAACACTGCTCTCATTTGCTGTTTCCAT
GAGGCTTGTGTATCTTTTGCAAGTGTCTCAACAGCAATCAACGTTTTTGCTATCACTTT
GGACAGATATGACATCTCTGTAAAACCTGCAAACCGAATTCTGACAATGGGCAGAGCTG
TAATGTTAATGATATCCATTTGGATTTTTTCTTTTTTCTCTTTCCTGATTCCTTTTATT
GAGGTAAATTTTTTCAGTCTTCAAAGTGGAAATACCTGGGAAAACAAGACACTTTTATG
TGTCAGTACAAATGAATACTACACTGAACTGGGAATGTATTATCACCTGTTAGTACAGA
TCCCAATATTCTTTTTCACTGTTGTAGTAATGTTAATCACATACACCAAAATACTTCAG
GCTCTTAATATTCGAATAGGCACAAGATTTTCAACAGGGCAGAAGAAGAAAGCAAGAAA
GAAAAAGACAATTTCTCTAACCACACAACATGAGGCTACAGACATGTCACAAAGCAGTG
GTGGGAGAAATGTAGTCTTTGGTGTAAGAACTTCAGTTTCTGTAATAATTGCCCTCCGG
CGAGCTGTGAAACGACACCGTGAACGACGAGAAAGACAAAAGAGAGTCTTCAGGATGTC
TTTATTGATTATTTCTACATTTCTTCTCTGCTGGACACCAATTTCTGTTTTAAATACCA
CCATTTTATGTTTAGGCCCAAGTGACCTTTTAGTAAAATTAAGATTGTGTTTTTTAGTC
ATGGCTTATGGAACAACTATATTTCACCCTCTATTATATGCATTCACTAGACAAAAATT
TCAAAAGGTCTTGAAAAGTAAAATGAAAAAGCGAGTTGTTTGTGCGGCCGCACGGGGAC
GCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACCGCCAGCTCCTCCCTG
GCCAAGGACACTTCATCGTGA
(SEQ ID No: 59)

FIGURE 6

A. Amino acid sequence of the β_2AR-V2R chimera

MGQPGNGSAFLLAPNRSHAPDHDVTQQRDEVWVVGMGIVMSLIVLAIVFGNVLVITAI
AKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLC
VTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRAT
HQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSE
GRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHV
IQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCARGRTPPSLGPQDESCTT
ASSSLAKDTSS
(Seq. ID No. 60)

B. Amino acid sequence of the MOR-V2R chimera

MDSSTGPGNTSDCSDPLAQASCSPAPGSWLNLSHVDGNQSDPCGLNRTGLGGNDSLCP
QTGSPSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFR
TPRNAKIVNVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIF
AFIMPILIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYVI
IKALITIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCAAARGRTPPSL
GPQDESCTTASSSLAKDTSS
(Seq. ID No. 61)

C. Amino acid sequence of the D1AR-V2R chimera

MAPNTSTMDEAGLPAERDFSFRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTNFF
VISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVDRY
WAISSPFQYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTWPLDGNFTSLEDTE
DDNCDTRLSRTYAISSSLISFYIPVAIMIVTYTSIYRIAQKQIRRISALERAAVHAKNCQTT
AGNGNPVECAQSESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFISNCMVPFCGSEET
QPFCIDSITFDVFVWFGWANSSLNPIIYAFNADFQKAFSTLLGCYRLCAAARGRTPPSLGP
QDESCTTASSSLAKDTSS
(Seq. ID No. 62)

Figure 6 (cont.)

D. Amino acid sequence of the 5HT1AR-V2R chimera

MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAA
IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVL
CCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED
RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT
RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHR
VGNSKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILC
WLPFFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCN
FCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(Seq. ID No. 63)

E. Amino acid sequence of the β3AR-V2R chimera

MAPWPHENSSLAPWPDLPTLAPNTANTSGLPGVPWEAALAGALLALAVLATVGGNLLV
IVAIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATGCELWTSV
DVLCVTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIM
SQWWRVGADAEAQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARVFVVA
TRQLRLLRGELGRFPPEESPPAPSRSLAPAPVGTCAPPEGVPACGRRPARLLPLREHRALC
TLGLIMGTFTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGYANSAFNPLIYCRSPDF
RSAFRRLLCRCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(Seq. ID No. 64)

F. Amino acid sequence of the Edg1R-V2R chimera

MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISADKENSIKLTSVVFILICCFIILE
NIFVLLTIWKTKKFHRPMYYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLRE
GSMFVALSASVFSLLAIAIERYITMLKMKLHNGSNNFRLFLLISACWVISLILGGLPIMGW
NCISALSSCSTVLPLYHKHYILFCTTVFTLLLLSIVILYCRIYSLVRTRSRRLTFRKNISKAS
RSSEKSLALLKTVIIVLSVFIACWAPLFILLLLDVGCKVKTCDILFRAEYFLVLAVLNSGT
NPIIYTLTNKEMRRAFIRIMSCCKCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(Seq. ID No. 65)

Figure 7


Bisindolylmaleimide III
Fpratns
Compound (μM)
0.01
0.1
1
10
100
0
100
200
300
400
500
600
700
▲B2AR RT
●B2AR CO2
□V2R RT
✕V2R CO2

Figure 8


Bisindolylmaleimide VI
Fgrains
Compound (μM)
0
100
200
300
400
500
600
700
0.01
0.1
1
10
100
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 9


Bisindolylmaleimide VII
Fgrains
Compound (μM)
0.01
0.1
1
10
100
0
100
200
300
400
500
600
700
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 10


4-amino-2-methyl-N-[2-[(2-nitrophenyl)thio]phenyl]-5-Pyrimidinemethanamine
Fgrains
700
600
500
400
300
200
100
0
0.01
0.1
1
10
100
Compound (μM)
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 11

RO-31-7549



Figure 12


RO-31-8425
Fgrains
Compound (μM)
0
100
200
300
400
500
600
700
0.01
0.1
1
10
100
▲B2AR RT
●B2AR CO2
□V2R RT
✕V2R CO2

Figure 13


5-[2-(5-Nitro-furan-2-yl)-vinyl]-furan-2-carboxylic acid methyl ester
Fgrains
Compound (μM)
0.01
0.1
1
10
100
0
100
200
300
400
500
600
700
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 14


3-tert-Butyl-2-propionyl-2H-indeno[1,2-c]pyrazol-4-one
Fgrains
Compound (µM)
0
100
200
300
400
500
600
700
0.01
0.1
1
10
100
▲B2AR RT
●B2AR CO2
□V2R RT
✕V2R CO2

Figure 15


Bisindolylmaleimide II
Grains
Compound (μM)
0
100
200
300
400
500
600
700
0.01
0.1
1
10
100
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 16


Bisindolylmaleimide III, Hydrochloride
Fgrains
700
600
500
400
300
200
100
0
0.01
0.1
1
10
100
Compound (μM)
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 17


Bisindolylmaleimide IV
Fgrains
Compound (μM)
0
100
200
300
400
500
600
700
0.01
0.1
1
10
100
▲B2AR RT
●B2AR CO2
□V2R RT
✕V2R CO2

Figure 18


Ketotifen fumarate salt
Fgrains
Compound (μM)
0.01
0.1
1
10
100
0
100
200
300
400
500
600
700
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 19


6-Fluoronorepinephrine, Hydrochloride
Frgrains
Compound (μM)
0
100
200
300
400
500
600
700
0.01
0.1
1
10
100
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 20


Sanguinarine Chloride (S5890)
Fgrains
Compound (µM)
0
100
200
300
400
500
600
700
0.01
0.1
1
10
100
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 21


Sanguinarine Chloride (LOPAC)
Fgrains
Compound (µM)
0
100
200
300
400
500
600
700
0.01
0.1
1
10
100
B2AR RT
B2AR CO2
V2R RT
V2R CO2

Figure 22

Propranolol
B2AR RT
B2AR CO2
V2R RT
V2R CO2
Fgrains
Compound (nM)
0
100
200
300
400
500
600
700
0.1
1
10
100
1000
10000